Drug Profile
CNTO 0007
Alternative Names: 42037788Latest Information Update: 21 Sep 2015
Price :
$50
*
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Developer Janssen Research & Development
- Class Neuroprotectants
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Stroke
Most Recent Events
- 21 Sep 2015 No recent reports of development identified - Phase-I for Stroke in USA (IV)
- 03 Feb 2011 Phase-I clinical trials for stroke in US (IV)